Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yasuharu Miyazawa"'
Autor:
Maki Asakura-Kinoshita, Takahiro Masuda, Kentaro Oka, Ken Ohara, Marina Miura, Masato Morinari, Kyohei Misawa, Yasuharu Miyazawa, Tetsu Akimoto, Kazuyuki Shimada, Daisuke Nagata
Publikováno v:
Diagnostics, Vol 14, Iss 11, p 1194 (2024)
We previously reported that sodium–glucose cotransporter 2 (SGLT2) inhibitors exert sustained fluid homeostatic actions through compensatory increases in osmotic diuresis-induced vasopressin secretion and fluid intake. However, SGLT2 inhibitors alo
Externí odkaz:
https://doaj.org/article/597a2bc7424444738dbeeea055f084cf
Autor:
Kentaro Oka, Takahiro Masuda, Ken Ohara, Marina Miura, Masato Morinari, Kyohei Misawa, Yasuharu Miyazawa, Tetsu Akimoto, Kazuyuki Shimada, Daisuke Nagata
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Sodium glucose cotransporter 2 (SGLT2) inhibitors have both glucose-lowering and diuretic effects. We recently reported that the SGLT2 inhibitor dapagliflozin exerts short-term fluid homeostatic action in patients with chronic kidney disease (CKD). H
Externí odkaz:
https://doaj.org/article/b2b3a875202b4264856082e8e140a1a2
Autor:
Ken Ohara, Takahiro Masuda, Masato Morinari, Mari Okada, Atsushi Miki, Saki Nakagawa, Takuya Murakami, Kentaro Oka, Maki Asakura, Yasuharu Miyazawa, Akito Maeshima, Tetsu Akimoto, Osamu Saito, Daisuke Nagata
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 12, Iss 1, Pp 1-9 (2020)
Abstract Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors are an antihyperglycemic drug with diuretic action. We recently reported that the SGLT2 inhibitor dapagliflozin ameliorates extracellular volume expansion with a mild increase in
Externí odkaz:
https://doaj.org/article/9eda7da41f604573a2ed614401e0ba1c
Autor:
Marina Kohara, Takahiro Masuda, Kazuhiro Shiizaki, Tetsu Akimoto, Yuko Watanabe, Sumiko Honma, Chuji Sekiguchi, Yasuharu Miyazawa, Eiji Kusano, Yoshinobu Kanda, Yasushi Asano, Makoto Kuro-O, Daisuke Nagata
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0178971 (2017)
Fibroblast growth factor 21 (FGF21) is an endocrine factor that regulates glucose and lipid metabolism. Circulating FGF21 predicts cardiovascular events and mortality in type 2 diabetes mellitus, including early-stage chronic kidney disease, but its
Externí odkaz:
https://doaj.org/article/f9e33daf9bdd49f091fea62fdf0c4e22
Autor:
Taro Sugase, Atsushi Miki, Shigeaki Muto, Hiromichi Yoshizawa, Tetsu Akimoto, Ken Ohara, Akito Maeshima, Takahiro Masuda, Chuji Sekiguchi, Osamu Saito, Yasuharu Miyazawa, Saki Nakagawa, Toshimi Imai, Takuya Murakami, Mari Okada, Akihiro Myoga, Daisuke Nagata
Publikováno v:
Nephrology.
AIM Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an antihyperglycemic drug with diuretic properties. We recently reported that an SGLT2 inhibitor ameliorated extracellular fluid expansion with a transient increase in urinary Na+ excretion. H
Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease
Autor:
Kazuhiro Shiizaki, Takahiro Masuda, Eiji Kusano, Sumiko Honma, Yasuharu Miyazawa, Marina Kohara, Daisuke Nagata, Makoto Kuro-o, Yasushi Asano, Tetsu Akimoto, Yuko Watanabe, Chuji Sekiguchi, Yoshinobu Kanda
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0178971 (2017)
PLoS ONE
PLoS ONE
Fibroblast growth factor 21 (FGF21) is an endocrine factor that regulates glucose and lipid metabolism. Circulating FGF21 predicts cardiovascular events and mortality in type 2 diabetes mellitus, including early-stage chronic kidney disease, but its
Publikováno v:
Neurology. 48(1)
It is not known whether lesions of the mammillary body per se can produce significant memory impairment in humans. The amnesia reported in patients with lesions in the mammillary bodies may have been produced by lesions coexisting in other memory-rel